Kudos to Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) for taking a leap forward in the war against diabetes. The two competitors-turned-partners for one joint venture recently announced the FDA and the European equivalent has accepted an application for permission to sell ertugliflozin and a couple of its derivatives. All the drugs/combos in question are part of the SGLT2 family, which essentially induce the kidneys to filter sugar out of the bloodstream for diabetics whose pancreas isn’t processing that sugar properly.
It’s an interesting approach, though not one without a potential downside. By forcing the kidneys to do something they weren’t meant to do, eventually, could pose new problems.
Cell MedX Corp (OTCMKTS:CMXC) is taking an entirely different approach to the treatment of diabetes. Rather than work around a failing pancreas as Merck and Pfizer have, Cell MedX is aiming to fix what’s broken for diabetics. That is, the company aims to restore a body’s cells that properly process sugar by turning them back “on” again using mild electrical currents.
As much as biologists and the healthcare industry know about the human body, new discoveries are being made all the time regarding our makeup. One of the more recent medical revelations was figuring out animals are not just a collection of chemicals and organic matter, but also electrical impulses. Yes, the human body creates electricity, but more than that, a body can benefit from mild electrical currents, as an electrical charge can put a damaged cell back into its natural, healthy state.
It may seem like a crazy idea at first, but know the FDA has already given the science of electromedicine the nod of approval as a treatment for chronic pain (called the Cefaly, if you’re curious), and some major companies are wading deeper into electromedicine waters.
As Scientific American’s Daisy Yuhas noted back in 2013:
Hot Medical Stocks To Invest In Right Now: Catabasis Pharmaceuticals, Inc.(CATB)
- [By Max Byerly]
These are some of the news articles that may have effected Accern’s analysis:
Get Catabasis Pharmaceuticals alerts:
Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf Emerging Consolidated Expectations, Analyst Ratings (finance.yahoo.com) Catabasis Pharmaceuticals Inc. – Receive News & Ratings Daily (thecasualsmart.com) Catabasis Pharmaceuticals (CATB) Upgraded by ValuEngine to Sell (americanbankingnews.com) Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10 (finance.yahoo.com) Catabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
A number of analysts recently issued reports on CATB shares. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Friday, January 26th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price (down previously from $5.00) on shares of Catabasis Pharmaceuticals in a research report on Wednesday, February 14th. Finally, ValuEngine raised Catabasis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Catabasis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $5.18.
Hot Medical Stocks To Invest In Right Now: Banner Corporation(BANR)
- [By Ethan Ryder]
Here are some of the news articles that may have impacted Accern’s rankings:
Get Banner alerts:
Banner Year for Asset Managers Could Be Catalyst for Change (markets.financialcontent.com) Zacks: Analysts Anticipate Banner Co. (BANR) to Announce $0.86 EPS (americanbankingnews.com) Banner Bank signs long lease for highly visible Sacramento site (finance.yahoo.com) Steven W. Rust Sells 511 Shares of Banner Co. (BANR) Stock (americanbankingnews.com) FY2018 Earnings Estimate for Banner Co. (BANR) Issued By DA Davidson (americanbankingnews.com)
NASDAQ BANR opened at $57.47 on Friday. The company has a quick ratio of 0.90, a current ratio of 0.92 and a debt-to-equity ratio of 0.24. The firm has a market cap of $1,896.48, a P/E ratio of 19.22, a PEG ratio of 1.66 and a beta of 0.96. Banner has a 1 year low of $52.07 and a 1 year high of $62.75.
Hot Medical Stocks To Invest In Right Now: Acacia Communications, Inc. (ACIA)
- [By Leo Sun]
That ban would cripple China’s 5G expansion efforts, since ZTE needs components from American companies like Acacia Communications (NASDAQ:ACIA) and Qualcomm. ZTE uses Acacia’s fiber optic components in its infrastructure upgrades, and Qualcomm’s SoCs in its smartphones.
- [By Benzinga News Desk]
President Donald Trump hinted he may intervene in the Justice Department’s Russia investigation, as a Senate panel advanced a measure to protect Special Counsel Robert Mueller: Link
USA GDP (QoQ) for Q1 2.30% vs 2.00% Est; Prior 2.90%
The University of Michigan's consumer confidence index for April is schedule for release at 10:00 a.m. ET.
The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET.
Data on farm prices for the recent week will be released at 3:00 p.m. ET.
Stifel upgraded Facebook (NASDAQ: FB) from Hold to Buy
Morgan Stanley upgraded Acacia Communications (NASDAQ: ACIA) from Underweight to Equal-Weight
Jefferies downgraded Sunoco (NYSE: SUN) from Hold to Underperform
KBW downgraded Oaktree Capital (NYSE: OAK) from Outperform to Market Perform
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
- [By Lisa Levin] Gainers
Precipio, Inc. (NASDAQ: PRPO) jumped 43.3 percent to $0.5447 after the micro-cap specialty diagnostics company reported preliminary first-quarter results. The company said its first quarter revenue rose 286 percent from the same quarter a year ago to $712,000.
Galectin Therapeutics, Inc. (NASDAQ: GALT) gained 34.5 percent to $4.52 after the company announced it would proceed with Phase 3 development of GR-MD-02 for NASH Cirrhosis following the FDA meeting.
Boxlight Corporation (NASDAQ: BOXL) shares rose 21.9 percent to $8.1063.
Evolus, Inc. (NASDAQ: EOLS) shares surged 16 percent to $15.65.
Myomo, Inc. (NYSE: MYO) shares jumped 15.5 percent to $3.6263 after the company disclosed that its application for Medicare codes received favorable preliminary decision.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) rose 13.7 percent to $10.12.
ProPhase Labs, Inc. (NASDAQ: PRPH) gained 13.7 percent to $4.6743.
Acacia Communications, Inc. (NASDAQ: ACIA) shares gained 12.2 percent to $35.34 as optical sector is seeing strength following President Trump's announcement that he would work with China related to ZTE Corp.
Tailored Brands, Inc. (NYSE: TLRD) shares rose 11.3 percent to $35.17. Jefferies upgraded Tailored Brands from Hold to Buy.
Kona Grill, Inc. (NASDAQ: KONA) jumped 10.6 percent to $2.875.
Federated National Holding Company (NASDAQ: FNHC) shares rose 10.6 percent to $20.29. Raymond James upgraded Federated National Holding from Outperform to Strong Buy.
Renewable Energy Group, Inc. (NASDAQ: REGI) climbed 10.2 percent to $15.15. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
Stein Mart, Inc. (NASDAQ: SMRT) shares climbed 10.1 percent to $3.16. Stein Mart is expected to release Q1 earnings on May 23.
NXP Semiconductors N.V. (NASDAQ: NXPI) rose 9.7 percent to $108.60 after Bloomberg reported that the China’s Commerce Ministry has restar
Hot Medical Stocks To Invest In Right Now: MarineMax, Inc.(HZO)
- [By Lisa Levin]
MarineMax, Inc. (NYSE: HZO) shares were also up, gaining 24 percent to $21.70 as the company posted upbeat Q2 results and raised its FY18 outlook.
Equities Trading DOWN
- [By Max Byerly]
MarineMax, Inc. (NYSE:HZO) EVP Charles A. Cashman sold 25,000 shares of the business’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $22.92, for a total value of $573,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
- [By Lisa Levin]
MarineMax, Inc. (NYSE: HZO) shares were also up, gaining 24 percent to $21.75 as the company posted upbeat Q2 results and raised its FY18 outlook.
Equities Trading DOWN